Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 18/20 | 0.83 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL4270336 | 0.94 | FDPS (0.87) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4284352 | 0.94 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4284362 | 0.91 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL6270347 | 0.91 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL18898 | 0.91 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL14645374 | 0.89 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL579001 | 0.89 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4646147 | 0.89 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL1115700 | 0.89 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL19614558 | 0.89 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150157650-A1 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE | INTERNATIONAL MEDICATION SYSTEMS, LIMITED | 2015-06-11 | — | — | US | disclosed |
| US-20150157649-A1 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE | INTERNATIONAL MEDICATION SYSTEMS, LIMITED | 2015-06-11 | — | — | US | disclosed |
| US-8974801-B2 | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate | AMPHASTAR PHARMACEUTICALS INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2548441-B1 | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate | AMPHASTAR PHARMACEUTICALS INC (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2548441-A1 | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate | Amphastar Pharmaceuticals Incorporation (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2120585-B1 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE | AMPHASTAR PHARMACEUTICALS INC (US) | 2012-10-03 | — | — | EP | disclosed |
| EP-2120585-A1 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE | Amphastar Pharmaceuticals Incorporation (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008085281-A1 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE | AMPHASTAR PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080153784-A1 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE | WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153784-A1 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE | SOST, PTH1R, BPGM | FDPS 841/4885PDE3A 326/4885LMNA 4276/4885 |
| US-20150157650-A1 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE | SOST, PTH1R, BPGM | FDPS 841/4885PDE3A 326/4885LMNA 4276/4885 |
| US-20150157649-A1 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE | SOST, PTH1R, BPGM | FDPS 841/4885PDE3A 326/4885LMNA 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.